about
The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) salineExercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and CAn official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstrictionPulmonary gas exchange response to exercise- and mannitol-induced bronchoconstriction in mild asthmaThe effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis.Effects of terbutaline in combination with mannitol on mucociliary clearance.Inhaled mannitol shifts exhaled nitric oxide in opposite directions in asthmatics and healthy subjects.Exercise-induced asthma: is it the right diagnosis in elite athletes?Airway hyperresponsiveness to methacholine, adenosine 5-monophosphate, mannitol, eucapnic voluntary hyperpnoea and field exercise challenge in elite cross-country skiersReproducibility of the airway response to an exercise protocol standardized for intensity, duration, and inspired air conditions, in subjects with symptoms suggestive of asthma.How does exercise cause asthma attacks?Methods for "indirect" challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols.A World Allergy Organization international survey on physical activity as a treatment option for asthma and allergies.Long-acting beta 2-adrenoceptor agonists and exercise-induced asthma: lessons to guide us in the future.Single-dose agents in the prevention of exercise-induced asthma: a descriptive review.Metabolic and ventilatory changes in asthmatic patients during and after exercise.Hyperosmolar agents and clearance of mucus in the diseased airway.Beta2-agonists and exercise-induced asthma.A standard, single dose of inhaled terbutaline attenuates hyperpnea-induced bronchoconstriction and mast cell activation in athletesProvocative challenges to help diagnose and monitor asthma: exercise, methacholine, adenosine, and mannitol.Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthmaAirway injury as a mechanism for exercise-induced bronchoconstriction in elite athletes.Asthma and the elite athlete: summary of the International Olympic Committee's consensus conference, Lausanne, Switzerland, January 22-24, 2008.Inspiratory flows and volumes in subjects with cystic fibrosis using a new dry powder inhaler device.Indirect challenge tests: Airway hyperresponsiveness in asthma: its measurement and clinical significance.Bronchial provocation testing: the future.Airway injury during high-level exercise.Assessment and prevention of exercise-induced bronchoconstriction.Pathogenesis of exercise-induced bronchoconstriction.Refractoriness to exercise challenge: a review of the mechanisms old and new.Assessment of EIB: What you need to know to optimize test results.Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis.Inhaled mannitol improves lung function in cystic fibrosis.Inhalation provocation tests using nonisotonic aerosols.The effects of mannitol on the transport of ciprofloxacin across respiratory epithelia.An evaluation of pharmacotherapy for exercise-induced asthma.Heterogeneity of mechanisms in exercise induced asthma.Air quality and temperature effects on exercise-induced bronchoconstriction.Is there a unifying hypothesis for exercise-induced asthma?Inspiratory Flows and Volumes in Subjects with Non-CF Bronchiectasis Using a New Dry Powder Inhaler Device.
P50
Q25255964-061057C1-2BA1-4AA6-9B2A-4D947A98EAD1Q28271205-4F3FA57D-BB5E-4565-ADB8-56E83E0D86F7Q28289889-707DA6BD-00FE-4FB0-9C00-7C4EBEDDAA16Q28292353-DEBB6835-720F-4C73-A380-0031F4162FF7Q30498416-9BF9BC42-9009-4FF1-A944-895FE051F891Q30721561-5C19B039-125C-488A-A33E-90A5141B268EQ31867127-359672C8-DCF6-4C13-AEF7-A4C2D1CBB57FQ34030789-18333802-34D0-4D87-A374-A7B79C38A2BFQ34125202-86BD0BE2-D8E8-4DF8-B28E-B971A4B25201Q34128467-0D9B8530-37DD-41D7-A723-C8DF69992434Q34498124-C5915869-B973-4947-8885-4A1414599839Q35088211-AFA0DC87-006A-4DC8-B82E-8CD89493B282Q35186730-22911830-F271-479B-BDFE-CBC29E14F592Q35788055-F7C33454-0BA3-4E76-A0D8-827FD39E7BC7Q36013683-738ADCC8-B9CC-4F08-96E7-69F173CC6172Q36425993-59130F47-338B-4C61-9ECA-F03C34FA5803Q36427309-97777FD5-A022-4D11-89C2-401A0259899DQ36645443-9CE2E21A-D2F2-4685-9D86-A54E857F8616Q36973812-4870A362-8AFA-4CDB-B15F-8C6CB65ABCADQ37016880-BCA34E90-2211-4ABD-8A64-9B26B032925CQ37102189-A67364FB-8CE2-498F-BF7D-726AC12686C0Q37191474-027EB165-55BB-45B3-BE05-64C15EF40CD8Q37234708-22EC912F-2C58-4208-AD2D-68E4A44F2006Q37601392-6B524F98-EC8A-49F2-94B1-62C2494B676CQ37776376-EEEBD74C-041E-435B-A00A-850C84EC8944Q37819869-6E17FD35-02AA-44B3-8081-8A56A2DEE368Q37976015-6917C112-701E-468E-A4EE-DAAA33BC6573Q37976017-145D2D0C-A88F-41AD-9DBB-3C17B26A4511Q38119617-8E5C43C4-E2ED-44C8-A6B4-351E1C592A93Q38119618-AD7E2BB4-246E-4BE1-B27E-14AB5A034BD4Q38119620-0953D539-338E-4B58-9ECA-E0C600992DBFQ38377995-A58C40BF-30D8-4795-9F6E-5159E8E2C08AQ38391625-A318E318-B1BD-42FF-AA54-3059EBB4EFA4Q38712493-ED85319C-37E7-42E7-8F80-302FAC466EBDQ39134662-ED324631-CBA5-4587-BB27-AF5AB3BE17F5Q39288186-B4B7CC28-57A9-42ED-A24B-DCAA177AFBEBQ39828550-8809FA27-8899-4685-B0E8-7CF8B07C8F7FQ40272925-320139F1-14EE-4B65-B667-8AD1B0ED8563Q41594849-3D269E03-2449-4F53-A3BA-962078CE59A9Q41975905-C0ABD575-9EF6-493C-9D4F-9F460F4CFCF5
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Sandra D Anderson
@nl
Sandra D Anderson
@sl
Sandra D. Anderson
@en
Sandra D. Anderson
@es
type
label
Sandra D Anderson
@nl
Sandra D Anderson
@sl
Sandra D. Anderson
@en
Sandra D. Anderson
@es
prefLabel
Sandra D Anderson
@nl
Sandra D Anderson
@sl
Sandra D. Anderson
@en
Sandra D. Anderson
@es
P108
P214
P244
P106
P1153
7404216161
P21
P214
P244
nb2013017259
P31
P496
0000-0002-6308-8770
P734
P735
P7859
lccn-nb2013017259